PTC Therapeutics (PTCT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PTCT PTC Therapeutics

Watchlist

42.990
-0.240-0.56%

Close Nov 25 16:00 ET

43.000
+0.010+0.02%

Post 19:54 ET

3.32BMarket Cap-7237P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Zhitong Finance34minutes ago
Express News | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters16:30 ET
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire16:30 ET
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Seeking Alpha15:10 ET
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $62
Moomoo NewsNov 19 07:31 ET · Ratings
Express News | PTC Therapeutics Inc : JP Morgan Raises Target Price to $62 From $51
ReutersNov 19 01:20 ET

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

mad541

May 20 07:38

$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻

Moomoo AI

Mar 3 08:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14 08:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Moomoo AI

Nov 18, 2023 08:43

PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.

PTC Therapeutics (NASDAQ:PTCT) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 68%

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

PTCT PTC Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target